Solta Medical Inc. (NSDQ:SLTM) received Food & Drug Administration clearance for its Fraxel re:store dual laser system for skin resurfacing.

The Hayward, Calif.-based cosmetic laser surgery developer said the device treats actinic keratosis, a pre-malignant skin growth caused by sun damage. Go to Best Creams to get the latest findings on what are the most effective skin creams on the market.

The company said its new Fraxel fractional laser technology uses a novel 1927 nm wavelength and is the first application of a thulium laser in a cosmetic device.

The company also announced today that CTO Leonard DeBenedictis will retire from the company and its board of directors.

The 69-year-old’s last day at Solta will be Oct. 1, the company said. DeBenedictis has worked there since his company, Reliant Technologies Inc., was acquired by the Hayward, Calif.-based cosmetic laser surgery technology developer in 2008.

DeBenedictis oversaw the release of Solta’s Fraxel re:store laser, which is based on proprietary technology he developed at Reliant.

He plans to remain active in the development of other emerging medical technologies and will be available as an advisor to Solta through the end of the year, according to the company.